Literature DB >> 21570852

CXCR3 antagonists: quaternary ammonium salts equipped with biphenyl- and polycycloaliphatic-anchors.

Maikel Wijtmans1, Dennis Verzijl, Serge Bergmans, Michael Lai, Leontien Bosch, Martine J Smit, Iwan J P de Esch, Rob Leurs.   

Abstract

Small-molecule ligands for the CXCR3 chemokine receptor receive considerable attention as a means to interrogate the roles of CXCR3 in vitro and in vivo and/or to potentially treat various conditions such as inflammatory diseases and cancer. We have synthesized and explored a novel class of small-molecule antagonists for CXCR3. A medium-throughput screen revealed an adamantane-guanidine as a hit. The guanidine unit was replaced by a small quaternary ammonium group, leading to ca. 5-fold increase in affinity. Substitution of the adamantane group by a myrtenyl moiety further increased affinity, while the benzyl group was decorated with an additional (substituted) aryl ring. This led to the identification of several bisaryl-based ligands with CXCR3 affinities of around 100 nM and with the ability to antagonize the functional activity of CXCL10.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21570852     DOI: 10.1016/j.bmc.2011.04.035

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  6 in total

1.  Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation.

Authors:  Graeme O'Boyle; Christopher R J Fox; Hannah R Walden; Joseph D P Willet; Emily R Mavin; Dominic W Hine; Jeremy M Palmer; Catriona E Barker; Christopher A Lamb; Simi Ali; John A Kirby
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-05       Impact factor: 11.205

Review 2.  Molecular mechanisms of liver metastasis.

Authors:  Kenji Kawada; Suguru Hasegawa; Teppei Murakami; Yoshiro Itatani; Hisahiro Hosogi; Masahiro Sonoshita; Takanori Kitamura; Teruaki Fujishita; Masayoshi Iwamoto; Takuya Matsumoto; Ryo Matsusue; Koya Hida; Gaku Akiyama; Kae Okoshi; Masahiro Yamada; Junichiro Kawamura; Makoto Mark Taketo; Yoshiharu Sakai
Journal:  Int J Clin Oncol       Date:  2011-08-17       Impact factor: 3.402

3.  Therapeutic efficacy of CXCR3 blockade in an experimental model of severe sepsis.

Authors:  Daniela S Herzig; Yin Guo; Geping Fang; Tracy E Toliver-Kinsky; Edward R Sherwood
Journal:  Crit Care       Date:  2012-09-19       Impact factor: 9.097

4.  CXCR3 antagonist VUF10085 binds to an intrahelical site distinct from that of the broad spectrum antagonist TAK-779.

Authors:  Belinda Nedjai; Jonathan M Viney; Hubert Li; Caroline Hull; Caroline A Anderson; Tomoki Horie; Richard Horuk; Nagarajan Vaidehi; James E Pease
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

5.  A toolbox of molecular photoswitches to modulate the CXCR3 chemokine receptor with light.

Authors:  Xavier Gómez-Santacana; Sabrina M de Munnik; Tamara A M Mocking; Niels J Hauwert; Shanliang Sun; Prashanna Vijayachandran; Iwan J P de Esch; Henry F Vischer; Maikel Wijtmans; Rob Leurs
Journal:  Beilstein J Org Chem       Date:  2019-10-23       Impact factor: 2.883

6.  Computational Study of C-X-C Chemokine Receptor (CXCR)3 Binding with Its Natural Agonists Chemokine (C-X-C Motif) Ligand (CXCL)9, 10 and 11 and with Synthetic Antagonists: Insights of Receptor Activation towards Drug Design for Vitiligo.

Authors:  Giovanny Aguilera-Durán; Antonio Romo-Mancillas
Journal:  Molecules       Date:  2020-09-25       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.